Cited by 266Acute Lymphoblastic Leukemia researchCell death mechanisms and regulationAcute Myeloid Leukemia Research

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

Peirs, Sofie, Matthijssens, Filip, Goossens, Steven, Van de Walle, Inge, Ruggero, Katia, de Bock, Charles E., Degryse, Sandrine, Canté-Barrett, Kirsten, Briot, Delphine, Clappier, Emmanuelle, Lammens, Tim, De Moerloose, Barbara, Benoit, Yves, Poppe, Bruce, Meijerink, Jules P., Cools, Jan, Soulier, Jean, Rabbitts, Terence H., Taghon, Tom, Speleman, Frank, Van Vlierberghe, Pieter·2014·Blood

DOI 10.1182/blood-2014-05-574566

Open this paper in CoChat — free account

Abstract

Key Points: High levels of the anti-apoptotic factor BCL-2 can be therapeutically exploited by the BH3 mimetic ABT-199 in human T-ALL.

Integrity signals

Registry

Crossref · 10.1182/blood-2014-05-574566

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
Oltersdorf, T., Elmore, S. W., Shoemaker, A. R., Armstrong, R. C., Augeri, D. J., Belli, B., Bruncko, M., Deckwerth, T. L., Dinges, J., Hajduk, P. J., et al. (2005) · Nature · doi:10.1038/nature03579 · Cited by 3,407
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Souers, A. J., Leverson, J. D., Boghaert, E. R., Ackler, S. L., Catron, N. D., Chen, J., Dayton, B. D., Ding, H., Enschede, S. H., Fairbrother, W. J., et al. (2013) · Nature Medicine · doi:10.1038/nm.3048 · Cited by 3,058
The Bcl-2 apoptotic switch in cancer development and therapy
Adams, J. M., & Cory, S. (2007) · Oncogene · doi:10.1038/sj.onc.1210220 · Cited by 2,256
GenePattern 2.0
Reich, M. M., Liefeld, T., Gould, J., Lerner, J., Tamayo, P., & Mesirov, J. P. (2006) · Nature Genetics · doi:10.1038/ng0506-500 · Cited by 2,053
ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor
Tse, C., Shoemaker, A. R., Adickes, J., Anderson, M. G., Chen, J., Jin, S., Johnson, E. F., Marsh, K. C., Mitten, M. J., Nimmer, P., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5836 · Cited by 1,992
Acute lymphoblastic leukaemia
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia
Ferrando, A. A., Neuberg, D. S., Staunton, J. E., Loh, M. L., Huard, C., Raimondi, S. C., Behm, F. G., Pui, C., Downing, J. R., Gilliland, D. G., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00018-1 · Cited by 1,130
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia
Coustan‐Smith, E., Mullighan, C. G., Onciu, M. M., Behm, F. G., Raimondi, S. C., Pei, D., Cheng, C., Su, X., Rubnitz, J. E., Basso, G., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70314-0 · Cited by 1,012
Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease
Roberts, A. W., Seymour, J. F., Brown, J. R., Wierda, W. G., Kipps, T. J., Khaw, S. L., Carney, D. A., He, S., Huang, D. C. S., Xiong, H., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.34.7898 · Cited by 855

Show all 44 references

Sorted by citations

The genetics and mechanisms of T cell acute lymphoblastic leukaemia
Belver, L., & Ferrando, A. A. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.63 · Cited by 460
Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
Jain, N., Lamb, A. V., O'Brien, S. M., Ravandi, F., Konopleva, M. Y., Jabbour, E. J., Zuo, Z., Jorgensen, J. L., Lin, P., Pierce, S. A., et al. (2016) · Blood · doi:10.1182/blood-2015-08-661702 · Cited by 354
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
Cang, S., Iragavarapu, C., Savooji, J., Song, Y., & Liu, D. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0224-3 · Cited by 289
Ex vivo drug response profiling detects recurrent sensitivity patterns in drug-resistant acute lymphoblastic leukemia
Frismantas, V., Dobay, M. P., Rinaldi, A. M., Tchinda, J., Dunn, S. H., Kunz, J. B., Richter‐Pechańska, P., Marovca, B., Pail, O., Jenni, S., et al. (2017) · Blood · doi:10.1182/blood-2016-09-738070 · Cited by 266
Genomics and drug profiling of fatal TCF3-HLF−positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options
Fischer, U., Förster, M., Rinaldi, A. M., Risch, T., Sungalee, S., Warnatz, H.-J., Bornhauser, B. C., Gombert, M., Kratsch, C., Stütz, A. M., et al. (2015) · Nature Genetics · doi:10.1038/ng.3362 · Cited by 262
Venetoclax: First Global Approval
Deeks, E. D. (2016) · Drugs · doi:10.1007/s40265-016-0596-x · Cited by 240
Advances in the Diagnosis and Treatment of Pediatric Acute Lymphoblastic Leukemia
Inaba, H., & Pui, C. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10091926 · Cited by 268
How I treat T-cell acute lymphoblastic leukemia in adults
Litzow, M. R., & Ferrando, A. A. (2015) · Blood · doi:10.1182/blood-2014-10-551895 · Cited by 227
Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia
Zhang, H., Nakauchi, Y., Köhnke, T., Stafford, M., Bottomly, D., Thomas, R., Wilmot, B., McWeeney, S. K., Majeti, R., & Tyner, J. W. (2020) · Nature Cancer · doi:10.1038/s43018-020-0103-x · Cited by 207
Acute lymphoblastic leukaemia
Pagliaro, L., Chen, S., Herranz, D., Mecucci, C., Harrison, C. J., Mullighan, C. G., Zhang, M., Zhu, C. H., Boissel, N., Winter, S. S., et al. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00525-x · Cited by 202
Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia
Khaw, S. L., Suryani, S., Evans, K., Richmond, J., Robbins, A. K., Kurmasheva, R. T., Billups, C. A., Erickson, S. W., Guo, Y., Houghton, P. J., et al. (2016) · Blood · doi:10.1182/blood-2016-03-707414 · Cited by 176
Emerging understanding of Bcl-2 biology: Implications for neoplastic progression and treatment
Correia, C., Lee, S. H., Meng, X. W., Vincelette, N. D., Knorr, K. L. B., Ding, H., Nowakowski, G. S., Dai, H., & Kaufmann, S. H. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2015.03.012 · Cited by 172
Physiological and Pharmacological Control of BAK, BAX, and Beyond
Luna-Vargas, M. P. A., & Chipuk, J. E. (2016) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.07.002 · Cited by 142
T-cell Acute Lymphoblastic Leukemia: A Roadmap to Targeted Therapies
Cordo’, V., van der Zwet, J. C. G., Canté-Barrett, K., Pieters, R., & Meijerink, J. P. P. (2020) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0093 · Cited by 148
Self-citation
Precision medicine in acute lymphoblastic leukemia
Pui, C. (2020) · Frontiers of Medicine · doi:10.1007/s11684-020-0759-8 · Cited by 142
The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells
Li, Z., He, S., & Look, A. T. (2018) · Leukemia · doi:10.1038/s41375-018-0201-2 · Cited by 132
A Novel l -Asparaginase with low l -Glutaminase Coactivity Is Highly Efficacious against Both T- and B-cell Acute Lymphoblastic Leukemias In Vivo
Nguyen, H. A. T., Su, Y., Zhang, J. Y., Antanasijevic, A., Caffrey, M. S., Schalk, A. M., Liu, L., Rondelli, D., Oh, A. L., Mahmud, D. L., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2106 · Cited by 130
Self-citation
Clinical Experience With Venetoclax Combined With Chemotherapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Richard‐Carpentier, G., Jabbour, E. J., Short, N. J., Rausch, C. R., Savoy, J. M., Bose, P., Yilmaz, M. E., Jain, N., Borthakur, G. M., Ohanian, M. N., et al. (2019) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2019.09.608 · Cited by 129
Found in Translation: How Preclinical Research Is Guiding the Clinical Development of the BCL2-Selective Inhibitor Venetoclax
Leverson, J. D., Sampath, D., Souers, A. J., Rosenberg, S. H., Fairbrother, W. J., Amiot, M., Konopleva, M. Y., & Letai, A. G. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0797 · Cited by 126
UTX inhibition as selective epigenetic therapy against TAL1-driven T-cell acute lymphoblastic leukemiaPreprint
Benyoucef, A., Palii, C. G., Wang, C., Porter, C. J., Chu, A., Dai, F., Tremblay, V., Rakopoulos, P., Singh, K., Huang, S., et al. (2016) · Genes & Development · doi:10.1101/gad.276790.115 · Cited by 130
Attacking cancer's Achilles heel: antagonism of anti‐apoptotic BCL ‐2 family members
Opferman, J. T. (2015) · FEBS Journal · doi:10.1111/febs.13472 · Cited by 118
Bax/Bcl-2 Cascade Is Regulated by the EGFR Pathway: Therapeutic Targeting of Non-Small Cell Lung Cancer
Alam, M., Alam, S., Shamsi, A., Adnan, M., Elasbali, A. M., Al‐Soud, W. A., Alreshidi, M. M., Hawsawi, Y. M., Tippana, A., Pasupuleti, V. R., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.869672 · Cited by 122
The Role of IL-7 and IL-7R in Cancer Pathophysiology and Immunotherapy
Wang, C., Kong, L.-Z., Kim, S., Lee, S., Oh, S., Jo, S., Jang, I.-H., & Kim, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810412 · Cited by 119
Novel biological insights in T-cell acute lymphoblastic leukemia
Durinck, K., Goossens, S., Peirs, S., Wallaert, A., Loocke, W. V., Matthijssens, F., Pieters, T., Milani, G., Lammens, T., Rondou, P., et al. (2015) · Experimental Hematology · doi:10.1016/j.exphem.2015.05.017 · Cited by 111
Self-citation
Safe targeting of T cell acute lymphoblastic leukemia by pathology-specific NOTCH inhibition
Habets, R., de Bock, C. E., Serneels, L., Lodewijckx, I., Verbeke, D., Nittner, D., Narlawar, R., Demeyer, S., Dooley, J., Liston, A., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6246 · Cited by 107
Self-citation
BH3-mimetics: recent developments in cancer therapy
Townsend, P. A., Kozhevnikova, M. V., Cexus, O., Zamyatnin, A. A., & Soond, S. M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02157-5 · Cited by 109
Expanding the Cancer Arsenal with Targeted Therapies: Disarmament of the Antiapoptotic Bcl-2 Proteins by Small Molecules
Yap, J. L., Chen, L., Lanning, M. E., & Fletcher, S. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01888 · Cited by 99
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia
Bassan, R., Bourquin, J., DeAngelo, D. J., & Chiaretti, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3648 · Cited by 100
T-Cell Acute Lymphoblastic Leukemia: Biomarkers and Their Clinical Usefulness
Bardelli, V., Arniani, S., Pierini, V., Giacomo, D. D., Pierini, T., Gorello, P., Mecucci, C., & Starza, R. L. (2021) · Genes · doi:10.3390/genes12081118 · Cited by 95
B Cell Lymphoma 2: A Potential Therapeutic Target for Cancer Therapy
Alam, M., Ali, S., Mohammad, T., Hasan, G. M., Yadav, D. K., & Hassan, M. I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910442 · Cited by 97
IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update
Oliveira, M. L., Akkapeddi, P., Ribeiro, D., Melão, A., & Barata, J. T. (2018) · Advances in Biological Regulation · doi:10.1016/j.jbior.2018.09.012 · Cited by 92
Relapsed T Cell ALL: Current Approaches and New Directions
McMahon, C. M., & Luger, S. M. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00501-3 · Cited by 87
Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
Degryse, S., de Bock, C. E., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., Jacobs, K., Binos, S., Skerrett-Byrne, D. A., Murray, H. C., et al. (2017) · Leukemia · doi:10.1038/leu.2017.276 · Cited by 86
Self-citation
Bcl-2 family of proteins as drug targets for cancer chemotherapy: the long way of BH3 mimetics from bench to bedside
Vela, L., & Marzo, I. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.05.014 · Cited by 86
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine
Morita, K., Jain, N., Kantarjian, H. M., Takahashi, K., Fang, H., Konopleva, M. Y., Hussein, S. E., Wang, F., Short, N. J., Maiti, A., et al. (2021) · American Journal of Hematology · doi:10.1002/ajh.26144 · Cited by 87
The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia
Lato, M., Przysucha, A., GROSMAN, S., Zawitkowska, J., & Lejman, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094502 · Cited by 84
Targeting Cancer Cell Mitochondria as a Therapeutic Approach: Recent Updates
Cui, Q., Wen, S., & Huang, P. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0011 · Cited by 83
Targeting BCL-2 and ABL/LYN in Philadelphia chromosome–positive acute lymphoblastic leukemia
Leonard, J. T., Rowley, J., Eide, C. A., Traer, E. A., Hayes‐Lattin, B., Loriaux, M., Spurgeon, S. E. F., Druker, B. J., Tyner, J. W., & Chang, B. H. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf5309 · Cited by 81
Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma
Chiron, D., Dousset, C., Brosseau, C., Touzeau, C., Maïga, S., Moreau, P., Pellat‐Deceunynck, C., Gouill, S. L., & Amiot, M. (2015) · Oncotarget · doi:10.18632/oncotarget.3275 · Cited by 80
The ribosomal RPL10 R98S mutation drives IRES-dependent BCL-2 translation in T-ALL
Kampen, K. R., Sulima, S. O., Verbelen, B., Girardi, T., Vereecke, S., Rinaldi, G., Verbeeck, J., de Beeck, J. O., Uyttebroeck, A., Meijerink, J. P. P., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0176-z · Cited by 76
Self-citation
MYC functions as a switch for natural killer cell-mediated immune surveillance of lymphoid malignancies
Swaminathan, S., Hansen, A. S., Heftdal, L. D., Dhanasekaran, R., Deutzmann, A., Mahauad‐Fernandez, W. D., Liefwalker, D. F., Horton, C. E., Mosley, A. R., Liebersbach, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16447-7 · Cited by 75
T-cell ligands modulate the cytolytic activity of the CD33/CD3 BiTE antibody construct, AMG 330
Laszlo, G. S., Gudgeon, C. J., Harrington, K. H., & Walter, R. B. (2015) · Blood Cancer Journal · doi:10.1038/bcj.2015.68 · Cited by 78
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
Smith, B. A. H., Deutzmann, A., Correa, K. M., Delaveris, C. S., Dhanasekaran, R., Dove, C. G., Sullivan, D. K., Wisnovsky, S., Stark, J. C., Pluvinage, J. V., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2215376120 · Cited by 74
Novel quinolone chalcones targeting colchicine-binding pocket kill multidrug-resistant cancer cells by inhibiting tubulin activity and MRP1 function
Lindamulage, I. K. S., Vu, H.-Y. T., Karthikeyan, C., Knockleby, J., Lee, Y.-F., Trivedi, P., & Lee, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-10972-0 · Cited by 72
Selective targeting of antiapoptotic BCL‐2 proteins in cancer
Timuçin, A. C., Başağa, H., & Kütük, Ö. (2018) · Medicinal Research Reviews · doi:10.1002/med.21516 · Cited by 73
Targeting BET proteins improves the therapeutic efficacy of BCL-2 inhibition in T-cell acute lymphoblastic leukemia
Peirs, S., Frismantas, V., Matthijssens, F., Loocke, W. V., Pieters, T., Vandamme, N., Lintermans, B., Dobay, M. P., Berx, G., Poppe, B. G., et al. (2017) · Leukemia · doi:10.1038/leu.2017.10 · Cited by 71
Self-citation
Strategies to Overcome Resistance Mechanisms in T-Cell Acute Lymphoblastic Leukemia
Follini, E., Marchesini, M., & Roti, G. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20123021 · Cited by 73
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study
Candoni, A., Lazzarotto, D., Ferrara, F., Curti, A., Lussana, F., Papayannidis, C., Principe, M. I. D., Bonifacio, M., Mosna, F., Delia, M., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.25957 · Cited by 69
Computer-Aided Drug Discovery for Undruggable Targets
Sun, Q., Wang, H., Xie, J., Wang, L., Mu, J., Li, J., Ren, Y., & Lai, L. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00969 · Cited by 72
Venetoclax for Children and Adolescents with Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma
Gibson, A., Trabal, A., McCall, D. C., Khazal, S. J., Toepfer, L., Bell, D., Roth, M. E., Mahadeo, K. M., Núnêz, C., Short, N. J., et al. (2021) · Cancers · doi:10.3390/cancers14010150 · Cited by 68
Prediction of venetoclax activity in precursor B-ALL by functional assessment of apoptosis signaling
Seyfried, F., Demir, S., Hörl, R. L., Stirnweiß, F. U., Ryan, J. A., Scheffold, A., Villalobos-Ortiz, M., Boldrin, E., Zinngrebe, J., Enzenmüller, S., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1801-0 · Cited by 64
How I treat adults with relapsed or refractory Philadelphia chromosome–negative acute lymphoblastic leukemia
Frey, N. V., & Luger, S. M. (2015) · Blood · doi:10.1182/blood-2014-09-551937 · Cited by 70
Accelerating Drug Development in Pediatric Cancer: A Novel Phase I Study Design of Venetoclax in Relapsed/Refractory Malignancies
Place, A. E., Goldsmith, K. C., Bourquin, J., Loh, M. L., Gore, L., Morgenstern, D. A., Sanzgiri, Y. D., Hoffman, D., Zhou, Y. Y., Ross, J. A., et al. (2018) · Future Oncology · doi:10.2217/fon-2018-0121 · Cited by 64
Enzyme-cleavable polymeric micelles for the intracellular delivery of proapoptotic peptides
Kern, H. B., Srinivasan, S., Convertine, A. J., Hockenbery, D., Press, O. W., & Stayton, P. S. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b01178 · Cited by 63
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway
Lonetti, A., Cappellini, A., Bertaina, A., Locatelli, F., Pession, A., Buontempo, F., Evangelisti, C., Evangelisti, C., Orsini, E., Zambonin, L., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0344-4 · Cited by 62
Multifaceted anticancer activity of BH3 mimetics: Current evidence and future prospects
Opydo‐Chanek, M., Gonzalo, Ó., & Marzo, I. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.03.006 · Cited by 60
Synergy of BCL2 and histone deacetylase inhibition against leukemic cells from cutaneous T-cell lymphoma patients
Cyrenne, B. M., Lewis, J. M., Weed, J. G., Carlson, K. R., Mirza, F. N., Foss, F. M., & Girardi, M. (2017) · Blood · doi:10.1182/blood-2017-06-792150 · Cited by 61
Targeting Cpt1a-Bcl-2 interaction modulates apoptosis resistance and fibrotic remodeling
Gu, L., Surolia, R., Larson‐Casey, J. L., He, C., Davis, D., Kang, J., Antony, V. B., & Carter, A. B. (2021) · Cell Death and Differentiation · doi:10.1038/s41418-021-00840-w · Cited by 59
SHQ1 regulation of RNA splicing is required for T-lymphoblastic leukemia cell survival
Su, H., Hu, J., Huang, L., Yang, Y., Thénoz, M., Kuchmiy, A. A., Hu, Y., Li, P., Feng, H., Zhou, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06523-4 · Cited by 56
Self-citation
Interplay between Mitochondrial Metabolism and Cellular Redox State Dictates Cancer Cell Survival
Foo, B. J.-A., Eu, J. Q., Hirpara, J. L., & Pervaiz, S. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/1341604 · Cited by 56
Trial watch: Tumor-targeting monoclonal antibodies for oncological indications
Vacchelli, E., Pol, J. G., Bloy, N., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Galon, J., Marabelle, A., Kohrt, H. E. K., Zitvogel, L., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.985940 · Cited by 59
Overexpression of wild-type IL-7Rα promotes T-cell acute lymphoblastic leukemia/lymphoma
Silva, A., Almeida, A. R. M., Cachucho, A., Neto, J. L., Demeyer, S., Matos, M., Hogan, T. V., Li, Y., Meijerink, J. P. P., Cools, J., et al. (2021) · Blood · doi:10.1182/blood.2019000553 · Cited by 54
Self-citation
Correction: Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
Degryse, S., de Bock, C. E., Demeyer, S., Govaerts, I., Bornschein, S., Verbeke, D., Jacobs, K., Binos, S., Skerrett-Byrne, D. A., Murray, H. C., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0241-7 · Cited by 54
Self-citation
Biology and Treatment Paradigms in T Cell Acute Lymphoblastic Leukemia in Older Adolescents and Adults
Patel, A. A., Thomas, J., Rojek, A. E., & Stock, W. (2020) · Current Treatment Options in Oncology · doi:10.1007/s11864-020-00757-5 · Cited by 52
First Report of Clinical Response to Venetoclax in Early T-Cell Precursor Acute Lymphoblastic Leukemia
Numan, Y., Alfayez, M., Maiti, A., Alvarado, Y., Jabbour, E. J., Ferrajoli, A., Konoplev, S. N., Kantarjian, H. M., & Bose, P. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00127 · Cited by 51
HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia
Akahane, K., Sanda, T., Mansour, M. R., Radimerski, T., DeAngelo, D. J., Weinstock, D. M., & Look, A. T. (2015) · Leukemia · doi:10.1038/leu.2015.222 · Cited by 49
A Novel BCL-2 Inhibitor APG-2575 Exerts Synthetic Lethality With BTK or MDM2-p53 Inhibitor in Diffuse Large B-Cell Lymphoma
Luo, Q., Pan, W., Zhou, S., Wang, G., Yi, H., Zhang, L., Yan, X., Yuan, L., Liu, Z., Wang, J., et al. (2020) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504020x15825405463920 · Cited by 48
Venetoclax and decitabine for treatment of relapsed T-cell acute lymphoblastic leukemia
Farhadfar, N., Li, Y., May, W. S., & Adams, C. B. (2020) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/j.hemonc.2019.10.002 · Cited by 49
Molecular mechanisms and therapeutic implications of tetrandrine and cepharanthine in T cell acute lymphoblastic leukemia and autoimmune diseases
Xu, W., Chen, S., Wang, X., Tanaka, S., Onda, K., Sugiyama, K., Yamada, H., & Hirano, T. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107659 · Cited by 49
The Role of Inhibition of Apoptosis in Acute Leukemias and Myelodysplastic Syndrome
McBride, A., Houtmann, S., Wilde, L. R., Vigil, C. E., Eischen, C. M., Kasner, M. T., & Palmisiano, N. D. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00192 · Cited by 49
Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol
Olivas-Aguirre, M., Torres-López, L., Pottosin, I. I., & Dobrovinskaya, O. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.617937 · Cited by 49
XPO1 inhibitor KPT-330 synergizes with Bcl-xL inhibitor to induce cancer cell apoptosis by perturbing rRNA processing and Mcl-1 protein synthesis
Zhu, Z., Liu, J., Yang, C., Zhao, M., & Xiong, Z. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1627-9 · Cited by 45
Therapeutic targeting of LCK tyrosine kinase and mTOR signaling in T-cell acute lymphoblastic leukemia
Laukkanen, S., Veloso, A. B., Yan, C., Oksa, L., Alpert, E. J., Do, D., Hyvärinen, N., McCarthy, K. M., Adhikari, A., Yang, Q., et al. (2022) · Blood · doi:10.1182/blood.2021015106 · Cited by 46
The path to venetoclax resistance is paved with mutations, metabolism, and more
Sullivan, G. P., Flanagan, L., Rodrigues, D. A., & Chonghaile, T. N. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abo6891 · Cited by 47
Advances in the Genetics and Therapy of Acute Lymphoblastic Leukemia
Chiaretti, S., Gianfelici, V., O'Brien, S. M., & Mullighan, C. G. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_156628 · Cited by 45
Inhibiting Janus Kinase 1 and BCL-2 to treat T cell acute lymphoblastic leukemia with IL7-Rα mutations
Senkevitch, E., Li, W., Hixon, J. A., Andrews, C., Cramer, S. D., Pauly, G. T., Back, T. C., Czarra, K., & Durum, S. K. (2018) · Oncotarget · doi:10.18632/oncotarget.25194 · Cited by 44
Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells
Xie, S. P., Jiang, H., Zhai, X., Fan, W. Q., Wang, S., Ding, J., & Chen, Y. (2016) · Acta Pharmacologica Sinica · doi:10.1038/aps.2016.49 · Cited by 44
Venetoclax and Bortezomib in Relapsed/Refractory Early T-Cell Precursor Acute Lymphoblastic Leukemia
Starza, R. L., Cambò, B., Pierini, A., Bornhauser, B. C., Montanaro, A., Bourquin, J., Mecucci, C., & Roti, G. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00172 · Cited by 43
Oncogenic transcriptional program driven by TAL1 in T-cell acute lymphoblastic leukemia
Tan, T. K., Zhang, C., & Sanda, T. (2018) · International Journal of Hematology · doi:10.1007/s12185-018-2518-z · Cited by 42
Mitochondria as emerging targets for therapies against T cell acute lymphoblastic leukemia
Olivas-Aguirre, M., Pottosin, I. I., & Dobrovinskaya, O. R. (2019) · Journal of Leukocyte Biology · doi:10.1002/jlb.5vmr0818-330rr · Cited by 42
Intracellular Cholesterol Pools Regulate Oncogenic Signaling and Epigenetic Circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia
Rashkovan, M., Alberó, R., Gianni, F., Perez-Duran, P., Miller, H. I., Mackey, A. L., Paietta, E. M., Tallman, M. S., Rowe, J. M., Litzow, M. R., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0551 · Cited by 42
Venetoclax in Combination with Decitabine for Relapsed T-Cell Acute Lymphoblastic Leukemia after Allogeneic Hematopoietic Cell Transplant
Rahmat, L. T., Nguyen, A., Abdulhaq, H., Prakash, S., Logan, A. C., & Mannis, G. N. (2018) · Case Reports in Hematology · doi:10.1155/2018/6092646 · Cited by 41
Deletion 6q Drives T-cell Leukemia Progression by Ribosome Modulation
Gachet, S., El-Chaar, T., Avran, D., Genescà, E., Catez, F., Quentin, S., Delord, M., Thérizols, G., Briot, D., Meunier, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0831 · Cited by 46
Self-citation
Targeting the Akt, GSK-3, Bcl-2 axis in acute myeloid leukemia
Ricciardi, M. R., Mirabilii, S., Licchetta, R., Piedimonte, M., & Tafuri, A. (2017) · Advances in Biological Regulation · doi:10.1016/j.jbior.2017.05.002 · Cited by 41
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia
Short, N. J., Jabbour, E. J., Jain, N., Senapati, J., Nasr, L. F., Haddad, F., Li, Z., Hsiao, Y.-C., Yang, J. J. J., Pemmaraju, N., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012231 · Cited by 38
The Emerging Role of Venetoclax-Based Treatments in Acute Lymphoblastic Leukemia
Aumann, S., Shaulov, A., Haran, A., Even‐Zohar, N. G., Vainstein, V., & Nachmias, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810957 · Cited by 41
Anti‐leukaemic activity of the TYK2 selective inhibitor NDI‐031301 in T‐cell acute lymphoblastic leukaemia
Akahane, K., Li, Z., Etchin, J., Berezovskaya, A., Gjini, E., Masse, C. E., Miao, W., Rocnik, J. L., Kapeller, R., Greenwood, J. R., et al. (2017) · British Journal of Haematology · doi:10.1111/bjh.14563 · Cited by 37
The promise of Janus kinase inhibitors in the treatment of hematological malignancies
Senkevitch, E., & Durum, S. K. (2016) · Cytokine · doi:10.1016/j.cyto.2016.10.012 · Cited by 38
Defining specificity and on-target activity of BH3-mimetics using engineered B-ALL cell lines
Koss, B. S., Ryan, J. A., Budhraja, A., Szarama, K. B., Yang, X., Bathina, M., Cardone, M. H., Nikolovska‐Coleska, Z., Letai, A. G., & Opferman, J. T. (2016) · Oncotarget · doi:10.18632/oncotarget.7204 · Cited by 36
Role of Autophagy and Apoptosis in Acute Lymphoblastic Leukemia
Huang, F., Yu, S., & Li, C. (2021) · Cancer Control · doi:10.1177/10732748211019138 · Cited by 34
Defining the molecular basis of oncogenic cooperation between TAL1 expression and Pten deletion in T-ALL using a novel pro-T-cell model system
Bornschein, S., Demeyer, S., Stirparo, R., Gielen, O., Vicente, C., Geerdens, E., Ghesquière, B., Aerts, S., Cools, J., & de Bock, C. E. (2017) · Leukemia · doi:10.1038/leu.2017.328 · Cited by 34
Self-citation
Bcl-2 family inhibitors sensitize human cancer models to therapy
Valentini, E., Martile, M. D., Brignone, M., Caprio, M. D., Manni, I., Chiappa, M., Sergio, I., Chiacchiarini, M., Bazzichetto, C., Conciatori, F., et al. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05963-1 · Cited by 35
Nanoformulated ABT-199 to effectively target Bcl-2 at mitochondrial membrane alleviates airway inflammation by inducing apoptosis
Tian, B., Li, F., Li, R., Hu, X., Lai, T., Lu, J., Zhao, Y. F., Du, Y., Liang, Z., Zhu, C., et al. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.06.020 · Cited by 31
JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia
Mansour, M. R., He, S., Li, Z., Lobbardi, R., Abraham, B. J., Hug, C. B., Rahman, S., León, T. E., Kuang, Y., Zimmerman, M. W., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20170484 · Cited by 32
Pre-clinical evaluation of second generation PIM inhibitors for the treatment of T-cell acute lymphoblastic leukemia and lymphoma
Smedt, R. D., Peirs, S., Morscio, J., Matthijssens, F., Roels, J., Reunes, L., Lintermans, B., Goossens, S., Lammens, T., Roy, N. V., et al. (2018) · Haematologica · doi:10.3324/haematol.2018.199257 · Cited by 31
Self-citation
Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison
Chong, S. J. F., Lai, J. X. H., Eu, J. Q., Bellot, G. L., & Pervaiz, S. (2017) · Antioxidants and Redox Signaling · doi:10.1089/ars.2017.7441 · Cited by 30
Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia
Luskin, M. R., Shimony, S. O., Keating, J. H., Winer, E. S., Garcia, J. S., Stone, R. M., Jabbour, E. J., Flamand, Y., Stevenson, K. E., Ryan, J. A., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2024014405 · Cited by 30
Therapeutic opportunities based on caspase modulation
Fulda, S. (2017) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2017.12.008 · Cited by 30
Targeting steroid resistance in T-cell acute lymphoblastic leukemia
Smedt, R. D., Morscio, J., Goossens, S., & Vlierberghe, P. V. (2019) · Blood Reviews · doi:10.1016/j.blre.2019.100591 · Cited by 30
Self-citation

Authors: Peirs, S., Matthijssens, F., Goossens, S., Van de Walle, I., Ruggero, K., de Bock, C. E., Degryse, S., Canté-Barrett, K., Briot, D., Clappier, E., Lammens, T., De Moerloose, B., Benoit, Y., Poppe, B., Meijerink, J. P., Cools, J., Soulier, J., Rabbitts, T. H., Taghon, T., Speleman, F., & Van Vlierberghe, P.
Affiliations: Center for Medical Genetics,
Vlaams Instituut voor Biotechnologie (BE)
Department of Clinical Chemistry, Microbiology and Immunology, Ghent University, Ghent, Belgium;
John Radcliffe Hospital (GB)
Laboratory for the Molecular Biology of Leukemia, Center for Human Genetics, University of Leuven and Center for the Biology of Disease, Vlaams Instituut voor Biotechnologie, Leuven, Belgium;
Erasmus MC (NL)
Inserm (FR)
Ghent University Hospital (BE)
Department of Pediatric Hematology-Oncology and Stem Cell Transplantation, Ghent University Hospital, Ghent, Belgium
Ghent University (BE)
ORCID: Peirs, Sofie
Matthijssens, Filip
Goossens, Steven
Ruggero, Katia
Degryse, Sandrine
Canté-Barrett, Kirsten
Clappier, Emmanuelle
Lammens, Tim
Poppe, Bruce
Meijerink, Jules P.
Cools, Jan
Soulier, Jean
Rabbitts, Terence H.
Taghon, Tom
Speleman, Frank
Venue: Blood
Publisher: American Society of Hematology
Published: 2014-12-11
Volume: 124
Issue: 25
Pages: 3738-3747
ISSN: 0006-4971 (ISSN-L)
1528-0020
DOI: 10.1182/blood-2014-05-574566
OpenAlex: W2048591984
Cited by: 264
References: 44
Citations by year: 2026: 12 · 2025: 18 · 2024: 31 · 2023: 29 · 2022: 24 · 2021: 25 · 2020: 22 · 2019: 25 · 2018: 22 · 2017: 18 · 2016: 22 · 2015: 16
FWCI: 18.58
Type: journal article
Language: en
Open access: closed
Locations: Blood (publishedVersion)
PubMed (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Funders: European Hematology Association (TRTH104)
Wellcome Trust (099246/Z/12/Z)
Agence Nationale de la Recherche (ANR-10-IBHU-0002)
Topics: Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords: venetoclax, BCL-2 inhibition, BH3 mimetics, T-cell acute lymphoblastic leukemia, drug synergy, doxorubicin, L-asparaginase, dexamethasone, TLX3, HOXA, TAL1, molecular subtypes, treatment resistance
MeSH terms: Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Cell Survival, Cells, Cultured, Child, Drug Synergism, Humans, Sulfonamides, Tumor Cells, Cultured, Blotting, Western, Gene Expression Regulation, Leukemic, Survival Analysis, Mice, SCID, Mice, Inbred NOD, Bridged Bicyclo Compounds, Heterocyclic, Jurkat Cells, Proto-Oncogene Proteins c-bcl-2, Inhibitory Concentration 50, Reverse Transcriptase Polymerase Chain Reaction, Oligonucleotide Array Sequence Analysis, Gene Expression Profiling, Xenograft Model Antitumor Assays, Cell Line, Tumor, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, HEK293 Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ABT-199 mediated inhibition of BCL-2 as a novel therapeutic strategy in T-cell acute lymphoblastic leukemia

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks